Amphastar on Tuesday received a complete response letter from the agency, which identified issues with a study assessing how humans interact with the device and device evaluation, among other concerns.
The drugmaker, which currently sells naloxone in pre-filled syringes, must address these issues with the nasal spray before resubmitting an application for FDA approval.
More articles on opioids:
Ohio couple criminally charged after 8-year-old son’s apparent heroin overdose
Nearly 70% of opioids not safely stored in households with children
Could medical marijuana help remedy the opioid epidemic?
